Axsome Therapeutics (AXSM) Q1 2026 earnings snapshot

Axsome Therapeutics (AXSM) has opened 2026 with Q1 revenue of US$191.2 million and a basic EPS loss of US$1.26, alongside a net loss of US$64.5 million, setting a clear benchmark for how the rest of the year might look. The company has seen revenue progress from US$118.8 million in Q4 2024 to US$191.2 million in Q1 2026, while trailing twelve month EPS has moved from a loss of US$5.99 to a loss of US$3.74 as revenue reached US$708.2 million over the same span. With the stock trading at US$223.06 and the story still centered on scaling revenue while working through sizeable losses, the focus now turns to how margins evolve from here.

See our full analysis for Axsome Therapeutics.

With the latest numbers in place, the next step is to see how this revenue growth and ongoing unprofitability line up against the widely followed narratives around Axsome's future growth, risk profile and path toward profitability.

Losses widen again to US$64.5 million

• Net loss in Q1 2026 was US$64.5 million, compared with US$28.6 million in Q4 2025 and US$59.4 million in Q1 2025, while trailing twelve month net loss sits at US$188.3 million on US$708.2 million of revenue.
• Bears argue that high spending will keep weighing on earnings, and the latest numbers give them some support:
  • Trailing twelve month losses have stayed large alongside growing revenue, with net loss of US$188.3 million versus US$638.5 million of revenue a year earlier and US$708.2 million now.
  • Q1 2026 EPS loss of US$1.26 follows a smaller EPS loss of US$0.56 in Q4 2025. Critics highlight this as evidence that the path to profitability may not be smooth even as the top line builds.

On this view, skeptics see the step up in recent losses as a reminder that Axsome still has a lot of cost to absorb before earnings turn positive, which keeps execution risk in focus. 🐻 Axsome Therapeutics Bear Case

Revenue now US$708.2 million over the last year

• Trailing twelve month revenue reached US$708.2 million in Q1 2026, up from US$638.5 million in Q4 2025 and US$385.7 million in Q4 2024, while trailing EPS loss narrowed from US$5.99 to US$3.74 over the same span.
• Bullish investors point to this combination of higher revenue and a smaller trailing EPS loss as fitting their growth thesis:
  • Revenue on a last twelve month basis has expanded by more than US$300 million since Q4 2024, which bullish narratives link to prescription growth across the CNS portfolio.
  • Trailing EPS loss improving from US$5.99 to US$3.74 sits alongside forecasts that earnings could grow about 57.2% per year. Bulls see this as early evidence that scale may eventually help margins.

For that bullish angle to play out, investors will be watching whether future quarters keep showing revenue growth alongside gradual improvement in per share losses. 🐂 Axsome Therapeutics Bull Case

Rich P/S multiple against peers

• With the stock at US$223.06 and trailing twelve month revenue of US$708.2 million, Axsome trades on a P/S of 16.2x, compared with a peer average of 8.8x and a US Pharmaceuticals industry average of 5.3x, while a DCF fair value of about US$628.25 sits well above the current share price and the allowed analyst price target of US$266.94.
• Consensus style narratives have to reconcile premium multiples with mixed valuation signals:
  • On one hand, a 16.2x P/S ratio is much higher than peer and industry levels, which can indicate that the market already assumes strong future growth and a shift to profitability.
  • On the other hand, the DCF fair value of roughly US$628.25 and an allowed target of US$266.94 both sit above the current US$223.06 price. Some investors may read this as suggesting more upside than the headline multiples alone imply.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Axsome Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views on losses, revenue and valuation running through this update, it helps to test the numbers yourself and form your own stance quickly. To see what is driving optimism on the opportunity side, check the 2 key rewards

See What Else Is Out There

Axsome is still posting sizeable losses alongside a rich 16.2x P/S multiple, which leaves little room for comfort if execution or expectations slip.

If that mix of high valuation and ongoing losses feels too tense, compare it with companies in the 72 resilient stocks with low risk scores that emphasize steadier earnings profiles and lower overall risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.